Parameswaran Venugopal

Author

Also Known As

Deepa Jagadeesh, Faisal Saghir, Melissa Larson, P Venugopal, P. Venugopal, Paramesaran Venugopal, Parameswaran Venugopal, Parameswaran Venugopal,, Parameswaren Venugopal, Parmeswaran Venugopal

240

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Rush University Medical Center Presbyterian St. Luke's Medical Center Rush University Northwestern University Cornell University

About

Parameswaran Venugopal is an author at Rush University Medical Center specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	30	1K
2	Cell Biology	10	10	290
3	Health Sciences	5	5	123
4	Public Health	1	1	13
5	Cellular Physiology	1	1	23

Parameswaran Venugopal

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Azra Raza, Peter Meyer, Diya Dutt, Blood	2001	303
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma John P. Leonard, Kathryn S. Kolibaba, James A. Reeves, Journal of Clinical Oncology	2017	187
Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes Vilasini Shetty, Suneel Mundle, Sairah Alvi, Leukemia Research Hematological MalignancyTumor BiologyBone Marrow FailureMyelodysplastic SyndromesMedicine	1996	179
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Blood	2021	122
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes Francesca Zorat, Vilasini Shetty, Diya Dutt, British Journal of Haematology	2001	106
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma Eric K. Rowinsky, Agne Paner, Jesús G. Berdeja, Investigational New Drugs	2020	91
Indication of an involvement of interleukin-1 beta converting enzyme- like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes SD Mundle, Parameswaran Venugopal, JD Cartlidge, Blood	1996	86
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression Azra Raza, Silvia Buonamici, Laurie Lisak, Leukemia Research Hematological MalignancyBone Marrow FailureMyelodysplastic Syndromes PatientsMedicineHematology	2004	78
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia Parameswaran Venugopal, Smitha Sivaraman, Xiaoke Huang, Leukemia Research Hematological MalignancyChronic Lymphocytic LeukemiaMalignant Blood DisorderImmunologyTumor Cells	2000	77
A paradigm shift in myelodysplastic syndromes. Azra Raza, Suneel Mundle, V. Shetty, PubMed	1996	69

Page 1